Expert Forum on Bladder Cancer: Nadofaragene Firadenovec for BCG-unresponsive NMIBC
“It is a promising drug in terms of the 3-month complete response rate,” says Chad Ritch, MD, MBA, FACS.
EP: 1.Expert Forum on Bladder Cancer: The BCG shortage
EP: 2.Expert Forum on Bladder Cancer: Bladder-sparing treatment
EP: 3.Expert Forum on Bladder Cancer: Nadofaragene Firadenovec for BCG-unresponsive NMIBC
EP: 4.Expert Forum on Bladder Cancer: Recent FDA approvals
EP: 5.Expert Forum on Bladder Cancer: Recent Innovations
EP: 6.Expert Forum on Bladder Cancer: Future Innovations
In this video Chad R. Ritch, MD, MBA, FACS,discusses the safety and efficacy of the novel agent nadofaragene firadenovec for patients with BCG-unresponsive non–muscle invasive bladder cancer.
This discussion is part of a larger forum on bladder cancer with Sam S. Chang, MD, MBA, and Chris B. Anderson, MD, MPH. Chang is a Patricia and Rodes Hart professor of urology and oncology at the Vanderbilt University Medical Center and chief surgical officer at the Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee. Ritch is an associate professor of urology and an associate director of UHealth International at the Miller School of Medicine, University of Miami, Florida. Anderson is an assistant professor of urology at Columbia University Irving Medical Center, Columbia University, New York City, New York.
Updates on advanced bladder cancer treatment
October 30th 2023"If a patient begins treatment with platinum-based chemotherapy and maintenance immune checkpoint inhibition, second-line options may involve evaluating erdafitinib, ADCs, or participation in clinical trials," says Adanma Ayanambakkam, MD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
